{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1350","value":"4134"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"403"}],"units":"Participants"}],"description":"Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted AUC for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with EC received lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.","id":"OG000","title":"Lenvatinib 20 mg + Pembrolizumab 200 mg"}],"paramType":"MEAN","populationDescription":"The population pharmacokinetic analysis set includes all the participants who have received at least 1 dose of study treatment with documented dosing history in the lenvatinib plus pembrolizumab arm, and have measurable plasma levels of lenvatinib. Here \"overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 0.5-10 hours post-dose; Cycle 1 Day 15: 0-12 hours post-dose; Cycle 2 Day 1: 0.5-10 hours post-dose (each cycle length=21 days)","title":"Model Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib","type":"SECONDARY","unitOfMeasure":"nanogram*hour per milliliter (ng*h/mL)"}